thiazolidinedione
Quick Summary
Thiazolidinediones are a class of oral antidiabetic drugs used to treat type II diabetes. They work by decreasing insulin resistance, primarily by activating PPARγ receptors in adipose tissue. This activation influences genes that regulate glucose and lipid metabolism.1
While thiazoles are a broader class of organic compounds with a ring structure containing carbon, nitrogen, and sulfur, and are found in natural products like vitamin B1 and synthetic drugs, thiazolidinediones are specifically used in diabetes management. Regular liver monitoring is necessary for individuals taking thiazolidinediones due to concerns about hepatotoxicity.21
Ask Britannica AI about this topic
Britannica doesn't have a full article on this topic, so we've curated a list of our relevant coverage.
diabetes mellitusDrugs used to control blood glucose levelsThiazolidinediones, such as rosiglitazone and pioglitazone, act by reducing insulin resistance of muscle and adipose cells and by increasing glucose transport into these tissues. These agents can cause edema (fluid accumulation in tissues), liver toxicity, and adverse cardiovascular events in certain patients. Furthermore, oral hypoglycemic…
Read MoreThiazolidinediones, such as rosiglitazone and pioglitazone, act by reducing insulin resistance of muscle and adipose cells and by increasing glucose transport into these tissues. These agents can cause edema (fluid accumulation in tissues), liver toxicity, and adverse cardiovascular events in certain patients. Furthermore, oral hypoglycemic…
Read More- antidiabetic drugOral antidiabetic drugs
The thiazolidinediones (e.g., pioglitazone, rosiglitazone) decrease insulin resistance. These oral hypoglycemic drugs exert their effects by activating so-called PPARγ (peroxisome proliferator-activated receptor-gamma) receptors, which are found primarily in adipose tissue; when activated, PPARγ prompts the transcription (synthesis of RNA
Read MoreThe thiazolidinediones (e.g., pioglitazone, rosiglitazone) decrease insulin resistance. These oral hypoglycemic drugs exert their effects by activating so-called PPARγ (peroxisome proliferator-activated receptor-gamma) receptors, which are found primarily in adipose tissue; when activated, PPARγ prompts the transcription (synthesis of RNA
Read More